The E3 ubiquitin-protein ligase Casitas B-lineage lymphoma protein (Cbl) negatively regulates epidermal growth factor receptor (EGFR) signaling pathway in many organisms, and has crucial roles in cell growth, development and human pathologies, including lung cancers. RING-SH2 Grb2 a chimeric protein of 215 amino acids containing the RING domain of Cbl that provides E3 ligase activity, and the SH2 domain of Grb2 that serves as an adaptor for EGFR. In this study, we demonstrated that RING-SH2 Grb2 could promote the ubiquitinylation and degradation of EGFR in a human non-small cell lung carcinoma cell line H1299. Moreover, we discovered that the RING-SH2 Grb2 chimera promoted the internalization of ligand-bound EGFR, inhibited the growth of H1299 cells, and significantly suppressed tumor growth in a xenograft mouse model. In summary, our results revealed a potential new cancer therapeutic approach for non-small cell lung cancer.
Introduction
The epidermal growth factor receptor (EGFR) is a member of the ErbB family, which regulates cell behavior in many aspects. Over-activation of EGFR signaling occurs in various types of cancer. EGFR gene amplification is frequently found in lung cancer (7, 21) , which is the leading cause of cancer-related deaths worldwide. Approximately 85% of lung cancer patients have non-small-cell lung carcinoma (NSCLC). Upon ligand binding to EGFR, the intracellular domain of the receptor is auto-phosphorylated and recruits growth factor receptor-binding protein 2 (Grb2), a down-stream molecule, leading to activation of Ras (24) . Ras activates Raf-MEK-ERK kinase cascades to promote cell proliferation. Moreover, the activation of Grb2 also activates the PI3K-Akt pathway through the Grb2-associated binder 1 (Gab1) to regulate cell survival (9) . Because activation of MAPK cascades results in cell growth, differentiation and inhibition of apoptosis, increased signaling is frequently associated with cancer progression (13, 14) .
Ubiquitinylation, a vital mechanism regulating EGFR signaling, is an enzymatic cascade involving ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitin-ligase (E3) enzymes. Ubiquitin is first activated through the binding E1 enzyme to form a E1-ubiquitin complex, followed by the transfer of ubiquitin to E2. E3 recognizes its substrates and draws the E2-ubiquitin complex in proximity, leading to the transfer of ubiquitin to the substrate (3) . c-Cbl is a RING-domain E3 ligase that acts as a multifunctional adaptor protein and participates in negative regulation of various types of signaling (18) . Cbl family proteins are composed of a conserved tyrosine kinase binding (TKB) domain, a RING domain at their Ntermini, and proline-rich domains at their C-termini in some members. EGFR, a substrate of c-Cbl, is negatively regulated by c-Cbl E3 ligase activity (18) . Following ligand binding to EGFR, Grb2 recruits c-Cbl through pY1068/pY1086 of EGFR, resulting in ubiquitinylation and sorting of EGFR into lysosomes where the receptor is degraded, leading to termination of EGFR signaling (20) . Alternatively, c-Cbl can be recruited directly to EGFR by docking to the pY1045 of EGFR to suppress EGFR signaling (10) . Thus, blocking EGFR endocytosis may result in increased signaling, and often leads to cancer progression (1). We previously discovered that the indirect interaction between D-CblL and EGFR through Drk, a Grb2 homologue in Drosophila, is critical for negative regulation of EGFR signaling by D-CblL (22) . We also found that RING-SH2 Drk , a fusion protein of the RING domain of D-CblL and the SH2 domain of Drk, efficiently downregulated the constitutively active EGFR signaling in Drosophila (22) . Based on these findings and their potential clinical relevance, we further investigated in this study the negative regulatory ability of RING-SH2 Grb2 in cancer cells expressing hyper-activated EGFR.
Here, we found that RING-SH2 Grb2 was sufficient to promote EGFR degradation, suppressing the proliferation of human non-small-cell lung cancer H1299 cells. Moreover, RING-SH2 Grb2 dramatically inhibited the growth of H1299 cells in a xenograft mouse model.
Materials and Methods

Plasmid Construction
The pCMV-HA-RING-SH2
Grb2 plasmid was generated by an in-frame fusion of the RING domain of c-Cbl and the SH2 domain of Grb2. The SH2 domain of Grb2 (342 bp) was amplified from pOTB7-Grb2 (ID3345524, Biosystems, Brava, Barcelona, Spain) by PCR using the following primers: 5'-ttggatccatagaaatgaaaccac atccgtggtttt ttggc-3' (forward), and 5'-tttctagattagagcgcctggacgtaggttgg-3' (reverse). Using this primer pair, BamHI and XbaI restriction enzyme sites were created at the 5' and 3' ends of the SH2 cDNA fragment, respectively. The RING domain of c-Cbl was amplified by PCR using a human brain cDNA library and the following primers: 5'-ttctcgaggtatggaccatatcaa agtgacccaggaa-3' (forward), and 5'-ttggatccttcatcatcat catcatcataatttgggg-3' (reverse). The XhoI and BamHI restriction sites were created at the 5' and 3' ends of the RING domain fragment, respectively. The pCMV-HA-R ING W408A -SH2 Grb2 mutant plasmid was generated using site-directed mutagenesis. The full-length fragment of c-Cbl was subcloned into a pIRES-AcGFP vector (Clontech, Mountain View, CA, USA) with the BamHI site from pSR-HA-c-Cbl (17) to generate pIRES-AcGFP-c-Cbl. The HA-RING-SH2 Grb2 fragment was subcloned into a pIRES-AcGFP vector with the SacII site from pCMV-HA-RING-SH2 Grb2 to generate pIRES-AcGFP-RING-SH2 Grb2 .
Cell Culture and Stable Clone Generation
The human non-small-cell lung cancer cell line H1299 was maintained in RPMI1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum in a 37°C incubator containing 5% CO 2 humidified air. Cells were transfected with the pIRESAcGFP vector, pIRES-AcGFP-c-Cbl and pIRESAcGFP-RING-SH2
Grb2 , respectively, with Lipofectamine2000 (Invitrogen Grand Island, NY, USA), according to the manufacturer's protocol. To obtain stably transfected clones, cells were selected using 500 μg/ml G418 (Life Technologies) for 3-4 weeks to generate H1299-vector, H1299-c-Cbl and H1299-RING-SH2
Grb2 cells that stably expressed GFP, c-Cbl and RING-SH2 Grb2 , respectively.
Immunoprecipitation and Western Blotting
Cells were lysed and sonicated in a lysis buffer (10 mM Tris, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 50 mM NaF, 20 mM Na 2 P 2 O 7 , 1 mM Na 3 VO 4 , 1 mM PMSF, 1 mM benzamidine, 0.5ìg/ml Leupeptin, and 1% Triton-X 100, pH7.4). Total cell lysates were separated using SDS-PAGE and blotted with anti-HA (1:200, Roche, Basel, Switzerland), anti-EGFR (1:500, Santa Cruz, Dallas, TX, USA), anti-ubiquitin (1:500, Cayman Chemical, Ann Arbor , MI, USA), anti-tubulin (1:500, Sigma, St. Louis, MO, USA), anti-pERK (1:200, Santa Cruz, CA, USA), or anti-ERK1 (1:200 Santa Cruz) antibodies. An ECL detection kit (Pierce, Rockford, IL, USA) was used to develop the signals. For immunoprecipitation, cell lysates containing 1.5 mg total protein were incubated with anti-EGFR (Santa Cruz) antibodies for 2 h at 4°C, followed by incubation with protein A sepharose beads (Pierce) for 2 h at 4°C. The precipitates were resolved using 7.5% SDS-PAGE.
Degradation Analysis and Signaling Assay
The H1299-EGFR cells, which stably express EGFR (19) , were transiently transfected with pC-MV-HA vector, pSR-HA-c-Cbl (17) or pCMV-HA-RING-SH2 Grb2 and were incubated at 37°C for 24 h. Following 3 h of serum free starvation, the cells were treated with 100 ng/ml of EGF and 25 μg/ml of cycloheximide (CHX) for 0, 2, 4 and 8 h. The cells were scraped and the amount of EGFR was analyzed by immunoblotting after EGF stimulation. The same transiently-transfected cells were starved for 3 h, and then treated with 50 ng/ml EGF, and cells were collected at 0, 5, 10 15 min for immunoblotting assay to determine the levels of ERK and p-ERK.
Internalization Assay
The H1299-EGFR cells, stably expressing EGFR (2), were transfected with the pCMV-HA vector, pSR-HA-c-Cbl or pCMV-HA-RING-SH2
Grb2 and incubated at 37°C for 24 h. Following 3 h of serum free starvation, the cells were treated with 100 ng/ml of Alexa Fluor488-conjugated EGF (Invitrogen, Grand Island, NY, USA) in a serum-free medium for 30 min at 4°C. After ligand binding, the cells were washed with cold PBS and transferred to 37°C to stimulate ligand-receptor complex internalization for 1, 3, and 5 min. The cells were washed with acid-stripping buffer (50 mM glycine, 150 mM NaCl, pH 1.5) and trypsinized followed by analysis by flow cytometer. The mean fluorescence intensity (MFI) of EGF-bound cells with or without acid-stripping buffer was designated respectively as the background or total MFI. The relative internalized intensity was then calculated by dividing the MFI at each time point by total MFI using the formula: MFI each time point -MFI background / MFI total -MFI background (4) .
Cell Number Assay
H1299 cells, stably expressing pIRES-GFP (H1299-vector), pIRES-GFP-c-Cbl (H1299-cCbl) or pIRES-GFP-RING-SH2
Grb2 (H1299-RING-SH2 Grb2 ), were seeded at a density of 1,000 cells per well in 96-well plates and were allowed to attach for 24 h. The cells were cultured in RPMI supplemented with 10% FBS for 2 to 4 days at the end of which a 
Cell Cycle Analysis
Cells expressing H1299-vector, H1299-c-Cbl or H1299-RING-SH2
Grb2 were starved for 1, 3 or 4 days to induce apoptosis. Subsequently, cells were harvested and fixed with 70% ethanol for 1 h. Following fixing, samples were washed with phosphate-buffered saline (PBS) and treated with 5 μg/ml of RNase A in PBS containing 0.5% TritonX-100 at 37°C for 1 h. The cells were stained with 50 μg/ml of propidium iodide (Sigma), and the DNA contents were quantified using a FACS caliber system. Ten thousand gated events per sample were acquired.
Xenograft Mouse Model
One million H1299-vector, H1299-c-Cbl or H1299-RING-SH2
Grb2 cells were subcutaneously injected into the back of the same nonobese diabetic severe combined immunodeficient (NOD-SCID) mice, respectively. Tumor size was monitored using a Vernier caliper at 1, 8, 11, 13, 15, 17 and 20 days after injection. Tumor volume was calculated with the following formula: (d 2 × D)/2, where d and D represent, respectively, the shortest and longest tumor diameters (2) . At the end of the experiments, the mice were sacrificed, and the tumors were removed and weighed. Procedures and the use of the animals were reviewed and approved by the Institutional Animal Care and Use Committee of National Taiwan University. Male nude mice (BALB/cAnN-Foxn1, 4 weeks old) were purchased from the National Laboratory Animal Center, Taiwan. Before treatment, the mice were anesthetized intraperitoneally with ketamine (5 μg/kg)-xylazine (0.5 μg/kg). All efforts were made to minimize suffering of animals.
Results
RING-SH2 Grb2 Promotes EGFR Ubiquitinylation and Degradation
Our previous work in Drosophila demonstrated that D-CblL-mediated down-regulation of EGFR signaling depended on the interaction with Drk, a Grb2 homologue. Two functional domains of D-CblL essential for this process are the RING domain and Drkinteracting domain. To directly target the E3 ligase activity of c-Cbl to EGFR for more efficient regulation, and to also to bypass the limited availability of Grb2, a chimeric protein RING-SH2 Drk , containing the RING domain and the SH2 domain of Drk, was generated. This chimera has been shown to promote ligand-receptor endocytosis and inhibition of EGFR signaling (22) . To investigate whether a human version of such a chimera could exert the same effects on EGFR signaling, RING-SH2 Grb2 , which is composed of the RING domain of c-Cbl and SH2 domain of Grb2 (Fig.  1A) , was generated and expressed in H1299-EGFR cells. To first examine the levels of EGFR ubiquitinylation in the cells, the RING-SH2
Grb2
, c-Cbl, or vector control was expressed in the H1299-EGFR cells (Fig.  1B) . Following EGF treatment, the levels of ubiquitinylated EGFR were significantly increased in c-Cbland RING-SH2
Grb2 -expressed cells relative to vector control (Fig. 1C) . This result indicates that RING-
SH2
Grb2 was recruited to EGFR and promoted its ubiquitinylation. To confirm that the increased EGFR ubiquitinylation required E3 ligase activity of the RING domain, a mutant RING W408A -SH2 Grb2 was generated in which the E3 ligase activity was abolished (4). The level of ubiquitinylated EGFR was not elevated in RING W408A -SH2 Grb2 -expressed cells, although the mutant protein could be recruited to the EGFR complex (Fig. 1B) . Therefore, the RING domain of c-Cbl could be recruited to activated-EGFR through the SH2 domain of Grb2 and promoted EGFR ubiquitinylation via its E3 ligase activity.
Following c-Cbl-mediated ubiquitinylation, the EGFR is targeted to lysosomal degradation (12) . Therefore, we further analyzed the amount of EGFR in H1299-EGFR cells expressing RING-SH2 Grb2 , c-Cbl or a vector. To measure the turnover rate of EGFR, the cells were treated with cycloheximide. As shown in Fig. 1D , the amount of EGFR was markedly reduced in RING-SH2
Grb2 or c-Cbl expressing cells after 2 h of EGF treatment. Taken together, the RING-SH2 Grb2 chimeric protein promoted EGFR ubiquitinylation and degradation in H1299-EGFR cells. These results indicate that, through merging with the substrate recognition domain of an adaptor, the RING domain could selectively target specific substrates. This strategy, therefore, has the advantage of target specificity by avoiding complex interactions with other possible c-Cbl substrates.
RING-SH2 Grb2 Down-Regulates EGFR Signaling by Suppressing MAPK Activation
Upon ligand binding to EGFR, EGFR is auto- -SH2 Grb2 were detected by western blotting using an antibody to EGFR and HA. (C) After stimulation with 100 ng/ml EGF, the cells were immunoprecipitated using anti-EGFR antibody and analyzed with antibodies to EGFR, HA or ubiquitin. (D) The turn-over of EGFR was analyzed by conducting a cycloheximide (CHX) chase experiment. Cell lysates were collected after 2, 4 and 8 h of treatment using 100 ng/ml EGF, and were subjected to western blotting with antibodies to EGFR and tubulin. The levels of EGFR were normalized with that of the tubulin control. (E) The Quantification of (D) where **P < 0.01. EGFR Tubulin phosphorylated and is recognized by Grb2. Grb2 initiates downstream signaling by recruiting SOS to Ras (1). Ras activates the kinase Raf-MEK-ERK kinase cascades to regulate the entry of cell cycle, and subsequently activates PI3K-PDK-Akt pathway to regulate cell survival. To test the ability of the chimeric protein RING-SH2 Grb2 to down-regulate EGFR signaling in H1299, EGFR signaling was examined by detecting the level of phosphorylated ERK (p-ERK) at several time points after EGF treatment. The levels of p-ERK were reduced in RING-SH2 Grb2 or c-Cbl expressing cells compared to that of vector expressing cells ( Figs. 2A and 2B) . These results suggest that the chimeric protein is capable of negatively regulating EGFR signaling by inhibiting MAPK activities.
RING-SH2 Grb2 Promotes EGFR Internalization
Previous studies on mammalian cells or Drosophila have consistently shown that Grb2-mediated c-Cbl recruitment to EGFR is required for EGFR internalization (8, 22) . We next tested whether the RING-SH2 Grb2 chimeric protein promotes EGFR internalization in H1299-EGFR cells. The percentages of cells with internalized EGF, as revealed by fluorescent intensity, elevated over time following EGF treatment in cells over-expressing the vector, c-Cbl or RING-SH2 Grb2 (Fig. 3A) . Under these conditions, similar numbers of cells bound with Alexafluor 488-conjugated EGF. However, H1299-EGFR cells expressing RING-SH2
Grb2 showed a significant increase in intensity at 5 min after EGF treatment as compared with 3 min of treatment (Fig. 3B) . In contrast, H1299-EGFR cells expressing the control vector exhibited no significant change in fluorescent intensities between these two time points. These results suggest that the RING-SH2 Grb2 chimeric protein promoted the kinetics of EGFR internalization in H1299-EGFR cells. Expression of c-Cbl also promoted EGF internalization between 3 and 5 min after EGF treatment, indicating that Grb2 may not be a determining factor for receptor internalization in H1299-EGFR cells (Fig. 3B) .
RING-SH2
Grb2 Suppresses H1299 Cell Growth In Vitro Mutant EGFR Y1045F enhances the mitogenic effect of EGF and leads to increased cell proliferation by reducing down-regulation of EGFR signaling (23) . Therefore, we further investigated the growth rate of H1299-RING-SH2
Grb2 cells using the MTS assay. Reduced growth rates of H1299-RING-SH2 Grb2 and H1299-c-Cbl cells were observed as compared with the H1299-vector cells (Fig. 4A) , supporting that RING-SH2 Grb2 inhibits cell proliferation through modulating the EGFR activity probably by promoting receptor ubiq- uitinylation and degradation. However, no significant apoptosis was observed in H1299-RING-SH2 Grb2 cells (Fig. 4B and Table 1 ), indicating that over-expression of this chimera did not induce cell toxicity. In many human lung cancer cell lines, activated EGFR is also known to facilitate adaptor Grb2 docking with Gab1 and the Shp-2 phosphatase to initiate PI3K signaling, which controls cell growth and survival (19) . Because the SH2 domain of this chimeric protein was derived from Grb2, it may compete with endogenous Grb2, blocking the downstream signaling and inhibiting cell growth. Indeed, inhibitors of Grb2 SH2 domain have been developed extensively for antagonizing RTK signaling in human disease (11) . Hence, the chimera reported here might serve dual roles in regulating EGFR signaling -targeting EGFR for degradation and suppressing signal transmission by competing with endogenous Grb2 functions.
Grb2 Suppresses Tumor Cell Growth In Vivo
We next examined whether RING-SH2 Grb2 suppressed H1299 cell growth in vivo in a xenograft mouse model. Stable clones of H1299 expressing RING-SH2 Grb2 , c-Cbl or vector alone, respectively, were injected subcutaneously into NOD-SCID mice and tumor growth was assessed. H1299-RING-SH2
Grb2 or H1299-c-Cbl cells developed tumors slower than did H1299-vector cells (Fig. 5A) , which was consistent with the in vitro growth assay data. Nevertheless, the effect of 
Grb2 on anti-mitogenic activities was more prominent than that of c-Cbl (Fig. 5C ). The average tumor mass of mice injected with H1299-RING-SH2 Grb2 cells was also significantly smaller than those of H1299-vector and H1299-c-Cbl cells (Fig. 5B) . The results indicated that RING-SH2 Grb2 was capable of suppressing tumor growth in vivo. These and our previous studies (22) showed that RING-SH2
Grb2 and RING-SH2 Drk could sufficiently down-regulate EGFR signaling in mice and Drosophila, implying evolutionary conservation of the molecular mechanism of c-Cbl-mediated regulation of EGFR signaling.
Discussion
EGFR gene amplification is found in nearly half of lung cancer patients. In addition, resistance to tyrosine kinase inhibitor-based targeted therapy is also frequently found in NSCLC patients. Therefore, development of alternative treatments for NSCLC is necessary. We have shown in this study for the first time that over-expression of the c-Cbl RING domain in conjunction with the SH2 domain of Grb2 is sufficient to down-regulate EGFR and to inhibit tumor growth in a mouse xenograft model of human lung cancer. Ubiquitinylation promotes membrane receptor for degradation through two processes, namely the ubiquitin proteasome system by multiple ubiquitination, and endocytosis and lysosomal degradation by monoubiquitination (5). The EGFR is known to be ubiquitinylated and degraded after internalization in the lysosome (6, 20) . The chimeric protein reported here, containing the RING domain of Cbl and the SH2 domain of Grb2, regulated EGFR signaling in the later process by promoting ubiquitination (Fig. 1C) and internalization of EGFR (Fig. 3) , leading to rapid degradation of EGFR (Figs. 1 D and E) . The substrate specificity in the ubiquitin-dependent degradation system is provided by E3 ligases which specifically recognize substrates by binging to activated receptors (15, 16) . This could be achieved by recruiting activated receptors through phosphorylated tyrosine of the receptor using the SH2 domain, or through an H1299 stable clones, which stably expressed a control vector (blue), c-Cbl (green) or RING-SH2 Grb2 (red). (A) Tumor size was calculated using the formula: width × length × height; *P = 0.0019 (B and C) Images (B) and weights (C) of the tumors isolated at the end of the experiments; *P = 0.0197, **P = 0.0069. The results in (A) and (C) represent mean ± SEM (n = 3). adaptor. In the case of EGFR, the Grb2 plays a crucial role in recruiting activated receptors. Indeed, here we demonstrated that a fusion protein containing only the E3 ligase functional domain of Cbl and the SH2 domain of Grb2 was sufficient to down-regulate EGFR activity in vitro in a cell culture system (Fig.  4) and in vivo in the mouse xenograft model (Fig. 5) . This strategy may also reduce positive effects of signal transduction mediated by Grb2 because the chimeric protein RING-SH2 Grb2 might compete with endogenous Grb2. Indeed, overexpression of RING-SH2
Grb2 had stronger effects than that of full-length c-Cbl in EGFR signaling (Fig. 2) and in the inhibition of tumor growth (Fig. 5) . Given that Cbl acts on many substrates, this strategy could potentially take advantage of the effect of Cbl while reducing the ability to interact with other substrates. Importantly, since c-Cbl also negatively regulates other receptor and non-receptor tyrosine kinases through its various interacting domains, exogenous expression of a chimera of the RING domain with a particular substrate-recognition domain may represent an effective therapeutic strategy for impeding cancer progression induced by other abnormal signaling.
